In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the...read more
Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, raised $233 million by offering 12.3 million shares at $19, above the range of $16 to $18. The company offered 2.0 million more shares than anticipated. At...read more
Updated Monday, 9/14. The post-Labor Day IPO frenzy is here as 14 IPOs plan to raise $7.8 billion in the coming week, led by cloud data unicorn Snowflake (SNOW). It is expected to be the biggest week for the IPO market by...read more
Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, announced terms for its IPO on Thursday. The Waltham, MA-based company plans to raise $175 million by offering 10.3 million shares at a price range of...read more
US IPO Weekly Recap: Snowflake's IPO breaks records in a diverse 15 IPO week
In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the...read more
Preclinical rare disease biotech Dyne Therapeutics prices upsized IPO at $19, above the range
Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, raised $233 million by offering 12.3 million shares at $19, above the range of $16 to $18. The company offered 2.0 million more shares than anticipated. At...read more
US IPO Week Ahead: The IPO market braces for a September SNOWstorm in a 14 IPO week
Updated Monday, 9/14. The post-Labor Day IPO frenzy is here as 14 IPOs plan to raise $7.8 billion in the coming week, led by cloud data unicorn Snowflake (SNOW). It is expected to be the biggest week for the IPO market by...read more
Preclinical rare disease biotech Dyne Therapeutics sets terms for $175 million IPO
Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, announced terms for its IPO on Thursday. The Waltham, MA-based company plans to raise $175 million by offering 10.3 million shares at a price range of...read more